Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:56 AM
Ignite Modification Date: 2025-12-25 @ 12:56 AM
NCT ID: NCT05978193
Eligibility Criteria: Inclusion Criteria: 1. Age ≥18; 2. Metastatic esophageal squamous cell carcinoma (stage IVB, M1) confirmed by pathology; 3. ECOG performance status: 0-1 point; 4. No prior anti-tumor treatment; 5. Adequate hematologic, renal, hepatic, and cardiac functions that meet the requirements for chemotherapy and immunotherapy assessed by investigators. Exclusion Criteria: 1. Non-squamous cell esophageal carcinoma or ESCC mixed with other pathological types of esophageal cancer; 2. Patients who are potentially curable with surgery as assessed by investigators; 3. Pleural metastasis or malignant pleural effusion, pericardial effusion; 4. Any prior anti-tumor therapy for esophageal cancer, i.e., surgery, radiotherapy, chemotherapy, or immunotherapy; 5. High risk of gastrointestinal bleeding, esophageal fistula, or perforation; 6. Patients with Patient-Generated Subjective Globe Assessment (PG-SGA) score≥9; 7. Unstable cardiac diseases or symptoms; 8. History of interstitial pulmonary disease, non-infectious pneumonitis; pulmonary fibrosis, or other uncontrolled acute pulmonary disease; 9. Active autoimmune disease or history of autoimmune disease; 10. Conditions of immunodeficiency or active infection requiring systemic therapy; 11. Pregnant or breastfeeding; 12. Patients with synchronous second primary cancer and a history of malignancy within the past 5 years (excluding completely cured cervical carcinoma in situ or basal cell or squamous cell skin carcinoma).
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT05978193
Study Brief:
Protocol Section: NCT05978193